Navigation Links
Watson's Nabumetone Tablets Receive FDA Approval
Date:6/17/2011

PARSIPPANY, N.J., June 17, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for Nabumetone Tablets USP, 500 mg and 750 mg. Watson expects to launch the product shortly.

Nabumetone had total U.S. sales of $58 million for the twelve months ending April 30, 2011, according to IMS Health.  Nabumetone is indicated for the relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended March 31, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. CONTACTS:Investors:Patty Eisenhaur(862) 261-8141Media:Charlie Mayr(862) 261-8030(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Receives Approval for Nabumetone Tablets
2. Breckenridge Announces Approval of Generic Activella® 0.5mg/0.1mg Tablets
3. Breckenridge Announces Approval of Letrozole Tablets
4. Mylan Receives Approval for Generic Version of Aricept® Tablets
5. Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S.
6. TPI Receives Production License for Its Anti-diabetic Drug Gliclazide Tablets from Chinas SFDA
7. Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S.
8. Mylan Launches Generic Version of Roxicodone® Tablets
9. Qualitest Receives FDA Approval for Dexamethasone Elixir, USP, 0.5mg/ 5 mL and Orsythia™ Tablets (Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.1 mg/0.02 mg)
10. Shionogi Inc. Announces Publication of Data in Pediatrics Demonstrating Efficacy of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets as Add-On Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
11. FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
(Date:6/23/2016)... June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
Breaking Medicine News(10 mins):